OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more
OptiNose (OPTN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.027x
Based on the latest financial reports, OptiNose (OPTN) has a cash flow conversion efficiency ratio of -0.027x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.67 Million) by net assets ($-61.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OptiNose - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how OptiNose's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OptiNose Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OptiNose ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAIGA BUILDING PRODS
F:4T7
|
N/A |
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
0.023x |
|
Hsin Yung Chien Co Ltd
TW:2114
|
0.010x |
|
First Northwest Bancorp
NASDAQ:FNWB
|
0.030x |
|
CONPET SA
RO:COTE
|
N/A |
|
Syncom Formulations (India) Limited
NSE:SYNCOMF
|
0.008x |
|
Daejoo Inc
KQ:003310
|
0.035x |
|
Yesco Holdings Co. Ltd
KO:015360
|
-0.068x |
Annual Cash Flow Conversion Efficiency for OptiNose (2015–2024)
The table below shows the annual cash flow conversion efficiency of OptiNose from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-40.36 Million | $-44.89 Million | 1.112x | +369.11% |
| 2023-12-31 | $-86.61 Million | $-20.53 Million | 0.237x | -80.16% |
| 2022-12-31 | $-56.62 Million | $-67.65 Million | 1.195x | -66.19% |
| 2021-12-31 | $-21.77 Million | $-76.94 Million | 3.534x | +127.82% |
| 2020-12-31 | $6.79 Million | $-86.21 Million | -12.700x | -761.19% |
| 2019-12-31 | $61.58 Million | $-90.81 Million | -1.475x | -90.50% |
| 2018-12-31 | $118.61 Million | $-91.82 Million | -0.774x | -235.46% |
| 2017-12-31 | $154.50 Million | $-35.65 Million | -0.231x | +95.92% |
| 2016-12-31 | $-3.84 Million | $21.72 Million | -5.659x | -635.04% |
| 2015-12-31 | $-27.15 Million | $-28.71 Million | 1.058x | -- |